PE
KROS icon

Point72 Europe’s Keros Therapeutics KROS Stock Holding History

Point72 Europe’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$601 Buy
+38
New +$561 ﹤0.01% 703

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 Europe's KROS Position: Q3 2025 in Review

Point72 Europe opened a new position in Keros Therapeutics (KROS) in Q3 2025: 38 shares worth $601. The stake represents ﹤0.01% of the portfolio and ranks #703 among its holdings.

155 funds tracked by Wall St. Rank hold KROS as of Q3 2025.

  • Point72 Europe held 38 shares of Keros Therapeutics worth $601 as of Q3 2025.
  • Keros Therapeutics was a new Point72 Europe position in Q3 2025.
  • Keros Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #703 holding.
  • 155 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.